Research Paper Volume 3, Issue 5 pp 515—532
Mutations in the BRCT binding site of BRCA1 result in hyper-recombination
Figure 7. RAD51 and RPA levels are elevated in human breast cancer tissue with a BRCA1 M1775R mutation. Human breast cancer tissue sections with the indicated BRCA1 germline mutations were immuno-stained for RAD51, RPA, and BRCA1 (WT, breast tumor with wild-type BRCA1 status; DCIS, ductal carcinoma in situ). Shown are representative malignant regions scored in yellow highlight in